Antiepileptic Drug Treatment in Children with Epilepsy

CNS Drugs

Volumn 29, Issue 10, 2015, Pages 847-863

  Rosati, Anna ^a   De Masi, Salvatore ^a   Guerrini, Renzo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CANNABINOID; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CORTICOTROPIN; ESLICARBAZEPINE ACETATE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; HYDROCORTISONE; LAMOTRIGINE; OXCARBAZEPINE; PERAMPANEL; PHENOBARBITAL; PHENYTOIN; PREDNISOLONE; PREGABALIN; RETIGABINE; RUFINAMIDE; STIRIPENTOL; SULTIAME; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ANTICONVULSANT THERAPY; BENIGN CHILDHOOD EPILEPSY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; CHILD; EPILEPSY;

ANTICONVULSANTS; CHILD; CLINICAL TRIALS, PHASE III AS TOPIC; EPILEPSY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84946543122     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-015-0281-8     Document Type: Review

References (118)

1. Wirrell EC. Predicting pharmacoresistance in pediatric epilepsy. Epilepsia. 2013;54(Suppl 2):19-22.
2. McCabe PH. New anti-epileptic drugs for the 21st century. Expert Opin Pharmacother. 2000;1:633-74.
3. The Epilepsies. The diagnosis and management of the epilepsies in adults and children in primary and secondary care. London: Published by the National Clinical Guideline Centre at The Royal College of Physicians; 2012. http://www.nice.org.uk/guidance/cg137. Accessed 24 Sep 2014.
4. de Silva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet. 1996;347:709-13.
5. Tudur Smith C, Marson AG, Clough HE, Williamson PR. Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database Syst Rev. 2002;(2):1-22. Art. No.: CD001911.
6. Tudur Smith C, Marson AG, Williamson PR. Carbamazepine versus phenobarbitone monotherapy for epilepsy. Cochrane Database Syst Rev. 2003;(1):1-22. Art. No.: CD001904.
7. Marson AG, Williamson PR, Clough H, Hutton JL, Chadwick DW, Epilepsy Monotherapy Trial Group. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia. 2002;43(5):505-13.
8. Gamble CL, Williamson PR, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev. 2006;(1):1-45. Art. No.: CD001031.
9. Zamponi N, Cardinali C. Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. Arch Neurol. 1999;56:605-7.
10. Sobaniec W, Kulak W, Strzelecka J, Smigielska-Kuzia J, Boćkowski L. A comparative study of vigabatrin vs. carbamazepine in monotherapy of newly diagnosed partial seizures in children. Pharmacol Rep. 2005;57:646-53.
11. Xiao Y, Gan L, Wang J, Luo M, Luo H. Vigabatrin versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev. 2012;(1):1-37. Art. No.: CD008781.
12. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia. 1998;39(Suppl 3):S2-10.
13. Canadian Study Group for Childhood Epilepsia. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia. 1998;39(9):952-9.
14. Keene DL, Whiting S, Humphrys P. Clobazam as an add on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci. 1990;17:317-9.
15. Cramer J, Sapin C, François C. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome. Acta Neurol Scand. 2013;128:91-9.
16. Hancock EC, Cross JH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2009;(2):1-43. Art. No.: CD003277.
17. Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia. 2009;50:1158-66.
18. Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA, OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011;77:1473-81.
19. Conry JA, Ng YT, Kernitsky L, et al. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia. 2014;55:558-67.
20. Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008;118:69-86.
21. Mikkelsen B, Birket-Smith E, Bradt S, et al. Clonazepam in the treatment of epilepsy. A controlled clinical trial in simple absences, bilateral massive epileptic myoclonus, and atonic seizures. Arch Neurol. 1976;33:322-5.
22. Dahlin M, Knutsson E, Amark P, Nergårdh A. Reduction of epileptiform activity in response to low-dose clonazepam in children with epilepsy: a randomized double-blind study. Epilepsia. 2000;41:308-15.
23. Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev. 2013;(6):1-69. Art. No.: CD001770.
24. Hrachovy RA, Frost JD, Glaze DG. High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms. J Pediatr. 1994;124:803-5.
25. Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomised, blinded study. Pediatrics. 1996;97:375-9.
26. Yanagaki S, Oguni H, Hayashi K, et al. A comparative study of high-dose and low-dose ACTH therapy for West syndrome. Brain Dev. 1999;21(7):461-7.
27. Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 1997;26:389-95.
28. Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet. 2004;364:1173-8.
29. Vigevano F, Cilio MR. Vigabatrin versus ACTH as first line treatment for infantile spasms: a randomised prospective study. Epilepsia. 1997;38:1270-4.
30. Askalan R, Mackay M, Brian J, et al. Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms. J Child Neurol. 2003;18(3):165-70.
31. Posner EB, Mohamed KK, Marson AG. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev. 2005;(4):1-17. Art. No.: CD003032.
32. Callaghan N, O'Hare J, O'Driscoll D, O'Neill B, Daly M. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev Med Child Neurol. 1982;24:830-6.
33. Sato S, White BG, Penry JK, Dreifuss FE, Sackellares JC, Kupferberg HJ. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology. 1982;32(2):157-63.
34. Martinovic Z. Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press; 1983:301-5.
35. Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia. 2004;45:1049-53.
36. Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010;362(9):790-9.
37. Nolan SJ, Tudur Smith C, Pulman J, Marson AG. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database Syst Rev. 2013;(1):1-35. Art. No.:CD002217.
38. Nolan SJ, Marson AG, Pulman J, Tudur Smith C. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database Syst Rev. 2013;(8):1-70. Art. No.: CD001769.
39. Milburn-McNulty P, Powell G, Sills GJ, Marson AG. Sulthiame add-on therapy for epilepsy. Cochrane Database Syst Rev. 2013;(3):1-16. Art. No.: CD009472.
40. Debus OM, Kurlemann G. Sulthiame in the primary therapy of West syndrome: a randomised double blind placebo-controlled add-on trial on baseline pyridoxine medication. Epilepsia. 2004;45:103-8.
41. Rating D, Wolf C, Bast T. Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia. 2000;41(10):1284-8.
42. Milburn-McNulty P, Powell G, Sills GJ, Marson AG. Sulthiame monotherapy for epilepsy. Cochrane Database Syst Rev. 2014;(3):1-29. Art. No.: CD010062.
43. Shi LL, Dong J, NiH, Geng J,Wu T. Felbamate as an add-on therapy for refractory epilepsy. Cochrane Database Syst Rev. 2011;(1):1-14. Art. No.: CD008295.
44. The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med. 1993;328:29-33.
45. Appleton R, Fichtner K, LaMoreaux L, et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group. Epilepsia. 1999;40(8):1147-54.
46. Al-Bachari S, Pulman J, Hutton JL, Marson AG. Gabapentin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2013;(7):1-43. Art. No.: CD001415.
47. Trudeau V, Myers S, LaMoreaux L, et al. Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol. 1996;11:470-5.
48. Tjia-Leong E, Leong K, Marson AG. Lamotrigine adjunctive therapy for refractory generalized tonic-clonic seizures. Cochrane Database Syst Rev. 2010;(12):1-16. Art. No.: CD007783.
49. Trevathan E, Kerls SP, Hammer AE, Vuong A, Messenheimer JA. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Pediatrics. 2006;118:e371-8.
50. Ramaratnam S, Marson AG, Baker GA. Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2001;(3):1-37. Art. No.: CD001909.
51. Duchowny M, Pellock JM, Graf WD, et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology. 1999;53(8):1724-31.
52. Piña-Garza JE, Levisohn P, Gucuyener K, et al. Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months. Neurology. 2008;70:2099-108.
53. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med. 1997;337(25):1807-12.
54. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998;39:508-12.
55. Mbizvo GK, Dixon P, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review. Cochrane Database Syst Rev. 2012;(9):1-76. Art. No.: CD001901.
56. Glauser TA, Ayala R, Elterman RD, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006;66(11):1654-60.
57. Levisohn PM, Mintz M, Hunter SJ, Yang H, Jones J, N01103 Levetiracetam Study Group. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia. 2009;50(11):2377-89.
58. de la Loge C, Hunter SJ, Schiemann J, Yang HC. Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial. Epilepsy Behav. 2010;18:291-8.
59. Fang Y, Wu X, Xu L, et al. Randomized-controlled trials of levetiracetam as an adjunctive therapy in epilepsy of multiple seizure types. J Clin Neurosci. 2014;21:55-62.
60. Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology. 2008;70(8):607-16.
61. Fattore C, Boniver C, Capovilla G, et al. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia. 2011;52:802-9.
62. Borggraefe I, Bonfert M, Bast T, et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). Eur J Paediatr Neurol. 2013;17:507-14.
63. Koch MW, Polman SKL. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009;(4):1-21. Art. No.: CD006453.
64. Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 1997;27:205-13.
65. Nolan SJ, Muller M, Tudur Smith C, Marson AG. Oxcarbazepine versus phenytoin monotherapy for epilepsy. Cochrane Database Syst Rev. 2013;(5):1-54. Art. No.: CD003615.
66. Glauser TA, Nigro M, Sachdeo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology. 2000;54:2237-44.
67. Zhou Q, Zheng J, Yu L, Jia X. Pregabalin monotherapy for epilepsy. Cochrane Database Syst Rev. 2012;(10):1-47. Art. No.: CD009429.
68. Pulman J, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2014;(3):1-65. Art. No.: CD005612.
69. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology. 2003;60(10):1631-7.
70. Pulman J, Hutton JL, Marson AG. Tiagabine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2014;(2):1-41. Art. No.: CD00190.
71. Sachdeo RC, Leroy RF, Krauss GL, et al. Tiagabine therapy for complex partial seizures: a dose-frequency study. Arch Neurol. 1997;54:595-601.
72. Uthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol. 1998;55:56-62.
73. Pulman J, Jette N, Dykeman J, Hemming K, Hutton JL, Marson AG. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2014;(2):1-52. Art. No.: CD001417.
74. Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology. 1999;52:1338-44.
75. Arroyo S, Dodson WE, Privitera MD, et al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand. 2005;112:214-22.
76. Ramsay E, Faught E, Krumholz A, et al. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia. 2010;51:1970-7.
77. Wheless JW, Neto W, Wang S, EPMN-105 Study Group. Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy. J Child Neurol. 2004;19(2):135-41.
78. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology. 1999;52:1882-7.
79. Hemming K, Maguire MJ, Hutton JL, Marson AG. Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev. 2013;(1):1-36. Art. No.: CD007302.
80. Grunewald RA, Thompson PJ, Corcoran R, Corden Z, Jackson GD, Duncan JS. Effects of vigabatrin on partial seizures and cognitive function. J Neurol Neurosurg Psychiatry. 1994;57:1057-63.
81. Loiseau P, Hardenberg JP, Pestre M, Guyot M, Schechter PJ, Tell GP. Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia. 1986;27:115-20.
82. Tassinari CA, Michelucci R, Ambrosetto G, Salvi F. Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Arch Neurol. 1987;44:907-10.
83. Appleton RE, Peters ACB, Mumford JP, Shaw DE. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia. 1999;40:1627-33.
84. Carmichael K, Pulman J, Lakhan SE, Parikh P, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2013;(12):1-38. Art. No.: CD001416.
85. Cross JH, Auvin S, Patten A, Giorgi L. Safety and tolerability of zonisamide in paediatric patients with epilepsy. Eur J Paediatr Neurol. 2014;18(6):747-58.
86. Guerrini R, Rosati A, Segieth J, Pellacani S, Bradshaw K, Giorgi L. A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia. 2013;54:1473-80.
87. Guerrini R, Rosati A, Bradshaw K, Giorgi L. Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55:568-78.
88. Chang XC, Yuan H, Wang Y, Xu HQ, Zheng RY. Eslicarbazepine acetate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2011;(12):1-41. Art. No.: CD008907.
89. Almeida L, Minciu I, Nunes T, et al. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J Clin Pharmacol. 2008;48:966-77.
90. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50:443-53.
91. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial onset seizures: a randomized controlled trial. Epilepsia. 2010;51(6):958-67.
92. Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78:1408-15.
93. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79:589-96.
94. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54:117-25.
95. Kramer LD, Satlin A, Krauss GL, et al. Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies. Epilepsia. 2014;55:423-31.
96. Splinter MY. Efficacy of retigabine in adjunctive treatment of partial onset seizures in adults. J Cent Nerv Syst Dis. 2013;5:31-41.
97. Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology. 2007;68:1197-204.
98. Biton V, Krauss G, Vasquez-Santana B, et al. A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia. 2011;52:234-42.
99. Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70:1950-8.
100. Kluger G, Glauser T, Krauss G, et al. Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand. 2010;122:202-8.
101. Wheless J, Conry J, Krauss G, et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol. 2009;24:1520-5.
102. Alsaad AM, Koren G. Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials. Br J Clin Pharmacol. 2014;78:1264-71.
103. Benedict A, Verdian L, Maclaine G. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK. Pharmacoeconomics. 2010;28:185-99.
104. Chiron C, Tonnelier S, Rey E, et al. Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. J Child Neurol. 2006;21:496-502.
105. Brigo F, Storti M. Stiripentol for focal refractory epilepsy. Cochrane Database Syst Rev 2014;(1):1-21. Art. No.: CD009887.
106. Brigo F, Storti M. Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy. Cochrane Database Syst Rev. 2013;(11):1-24. Art. No.: CD010483.
107. Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO Study Group. Lancet. 2000;356:1638-42.
108. Guerrini R, Tonnelier S, d'Athis P, et al. Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled Italian trial. Epilepsia. 2002;43(Suppl 8):155.
109. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014;(3):1-23. Art.No.:CD009270.
110. Guerrini R. Epilepsy in children. Lancet. 2006;367:499-524.
111. Institute of Medicine. Initial National priorities for comparative effectiveness research. Washington, DC: The National Academies Press; 2009.
112. French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf. 2011;2:141-58.
113. Patsalos PN, Fröscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43:365-85.
114. Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009;61:197-216.
115. Johannessen SI, Landmark CJ. Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol. 2010;8:254-67.
116. Guerrini R, Zaccara G, la Marca G, Rosati A. Safety and tolerability of antiepileptic drug treatment in children with epilepsy. Drug Saf. 2012;35:519-33.
117. Wyllie E, Gupta A, Lachhwani DK. The treatment of epilepsy. Principles and practice. 4th ed. Philadelphia: Lippincott, Williams and Wilkins; 2006.
118. Schiemann-Delgado J, Yang H, Loge Cde L, et al. A long-term open-label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4 to 16 years with partial-onset seizures. J Child Neurol. 2012;27:80-9.